(6R,10R,11R,12Z,17Z,19Z,21S)-6-[2-(diethylamino)ethanesulfonyl]-21-hydroxy-11,19-dimethyl-10-(propan-2-yl)-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.0^{3,7}]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone

• ChemBase编号: 1537
• 分子式: C34H50N4O9S
• 平均质量: 690.8472
• 单一同位素质量: 690.3298502
• SMILES: S(=O)(=O)([C@H]1C2N(CC1)C(=O)c1nc(oc1)CC(=O)C[C@H](O)/C=C(\C=C/CNC(=O)/C=C\[C@H]([C@H](OC2=O)C(C)C)C)/C)CCN(CC)CC
• Canonical SMILES: CCN(CCS(=O)(=O)[C@@H]1CCN2C1C(=O)O[C@H](C(C)C)[C@H](C)/C=C\C(=O)NC/C=C\C(=C/[C@H](CC(=O)Cc1nc(C2=O)co1)O)\C)CC
• InChI: InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9-,12-11-,23-18-/t24-,25-,28-,31?,32-/m1/s1
• InChIKey: SUYRLXYYZQTJHF-FUODUHIRSA-N

名称和登记号

名称

• IUPAC标准名: (6R,10R,11R,12Z,17Z,19Z,21S)-6-[2-(diethylamino)ethanesulfonyl]-21-hydroxy-11,19-dimethyl-10-(propan-2-yl)-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.0^{3,7}]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
• IUPAC传统名: (6R,10R,11R,12Z,17Z,19Z,21S)-6-[2-(diethylamino)ethanesulfonyl]-21-hydroxy-10-isopropyl-11,19-dimethyl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.0^{3,7}]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
• 别名: Dalfopristina [inn-spanish]; Dalfopristine [inn-french]; Dalfopristinum [inn-latin]; Dalfopristin

登记号

• CAS号: 112362-50-2
• PubChem SID: 46506561; 160964994
• PubChem CID: 21943991

理论计算性质

JChem

• Acid pKa: 11.378627
• 质子受体: 9
• 质子供体: 2
• LogD (pH = 5.5): -0.012025763
• LogD (pH = 7.4): 1.4094774
• Log P: 1.581891
• 摩尔折射率: 182.8398 cm^3
• 极化性: 70.6918 Å^3
• 极化表面积: 176.42 Å^2
• 可自由旋转的化学键: 7
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 2.57
• LOG S: -3.98
• 溶解度: 7.16e-02 g/l

详细说明

DrugBank - DB01764

• Drug Groups: approved
• Description: Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
• Indication: For the treatment of bacterial infections (usually in combination with quinupristin).
• Pharmacology: Dalfopristin is a streptogramin antibiotic, derived from pristinamycin IIA.
• Affected Organisms: Enteric bacteria and other eubacteria
• Biotransformation: Converted to an active non-conjugated metabolite by hydrolysis.
• Half Life: The elimination half-life is approximately 0.70 hours.
• Protein Binding: Moderate
• References: Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. [Pubmed] ; Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. [Pubmed] ; Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. [Pubmed] ; Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. [Pubmed]
• External Links: Wikipedia

参考文献

• Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. Pubmed
• Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. Pubmed
• Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. Pubmed
• Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. Pubmed